If necessary, cancel or reduce the dose of one of methyltrienolone injectable vitamins drug active ingredients they are administered as separate preparations of abacavir , lamivudine output and zidovudine .
Categories patients Adults and children over 12 years of age the recommended for adults and children over 12 years -. 1 tablet 2 times a day, regardless of meals If the mass of the body of a teenager or an adult less than 40 kg, is not appointed as the dose of each active ingredient in the tablet is fixed, ie, dose reduction for each active substance alone is not possible.
Elderly Data on the pharmacokinetics and there are no individuals. In connection with the possibility of age-related changes, including a decline in renal function and haematological disorders, the purpose persons in this age group requires special care.
Patients with impaired renal function impaired renal function may require a dose reduction of lamivudine or zidovudine. Patients with impaired renal function (creatinine clearance less than 50 mL / min), recommended to prescribe abacavir, lamivudine and zidovudine as separate medicines. Patients with impaired liver function in patients with liver function disorders is contraindicated. Dosage adjustment in the development of hematologic undesirable reactions When hemoglobin level of less than 9 g / dL (5.59 mmol / l) or neutrophils in the blood of less than 1.0 x 10 9 / l may require a dosage adjustment zidovudine. With the development of these unwanted reactions abacavir, lamivudine and zidovudine are administered in separate preparations.
As Trizivir composition includes abacavir, lamivudine and zidovudine, it may cause the same adverse reactions, that these three drugs alone . With respect to a large number of the following adverse events is not known, whether they are related to the action of the active ingredient, as well as broad spectrum commonly prescribed drugs for the treatment of infection, or recorded adverse events are the result of pathological processes underlying disease.
Data needed to fully assess the safety , so far is not enough.
Hypersensitivity to abacavir .
According to clinical studies, approximately 5% of patients taking abacavir hypersensitivity reaction is observed in rare cases, fatal. For this reaction is characterized by multi-organ failure.
The majority of patients with hypersensitivity in the development of this reaction is observed fever and / or rash (usually maculo-papular or urticaria), which methyltrienolone injectable vitamins are part of the manifestations of the syndrome, although in some cases these symptoms are absent.
The symptoms of this reaction are appear at any time after the initiation of treatment with abacavir, but often they occur within the first 6 weeks of treatment (median time of the beginning of the reaction – 11 days).
Manifestations of hypersensitivity reaction are listed below. Symptoms occurring not less than 10% of patients with hypersensitivity, are highlighted in bold.
Skin and skin appendages: rash (usually maculo-papular or urticaria). On the part of the gastrointestinal tract : nausea, vomiting, diarrhea, abdominal pain , ulceration of the mucous membranes of the mouth, hepatitis. respiratory system : shortness of breath, cough, sore throat, adult respiratory distress syndrome, respiratory failure. On the part of the central nervous system : headache, paresthesia. From the hematopoietic system and lymphatic system : lymphopenia . liver and pancreas : increase in liver enzymes, liver failure. From the musculoskeletal system : myalgia, rarely – myolysis, arthralgia, increased creatine kinase activity. From the urinary system : increased creatinine concentration in plasma, kidney failure. Other: . fever, fatigue, malaise, drowsiness, edema, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis patients with hypersensitivity to abacavir in the beginning can take it for any disease of the lungs and respiratory tract (pneumonia, bronchitis, pharyngitis), a flu-like methyltrienolone injectable vitamins syndrome , gastroenteritis or reactions to other undesirable products.